185 related articles for article (PubMed ID: 36243499)
1. Molecular and Anatomic Imaging of Neuroendocrine Tumors.
Szidonya L; Park EA; Kwak JJ; Mallak N
Surg Oncol Clin N Am; 2022 Oct; 31(4):649-671. PubMed ID: 36243499
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine Tumors: Diagnostics.
Sakellis C; Jacene HA
PET Clin; 2024 Jul; 19(3):325-339. PubMed ID: 38714399
[TBL] [Abstract][Full Text] [Related]
3. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
Adnan A; Basu S
J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.
Ito T; Jensen RT
Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):15-24. PubMed ID: 27875420
[TBL] [Abstract][Full Text] [Related]
5. PET Imaging of Neuroendocrine Tumors.
Galgano SJ; Wei B; Rose JB
Radiol Clin North Am; 2021 Sep; 59(5):789-799. PubMed ID: 34392919
[No Abstract] [Full Text] [Related]
6. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
8. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Maximum Standardized Uptake Value in 68Ga-Somatostatin Receptor Positron Emission Tomography for Neuroendocrine Tumors: A Systematic Review and Meta-analysis.
Lee DY; Kim YI
Clin Nucl Med; 2019 Oct; 44(10):777-783. PubMed ID: 31283601
[TBL] [Abstract][Full Text] [Related]
10. Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.
Squires MH; Volkan Adsay N; Schuster DM; Russell MC; Cardona K; Delman KA; Winer JH; Altinel D; Sarmiento JM; El-Rayes B; Hawk N; Staley CA; Maithel SK; Kooby DA
Ann Surg Oncol; 2015 Jul; 22(7):2295-301. PubMed ID: 25786743
[TBL] [Abstract][Full Text] [Related]
11. Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours.
Cuccurullo V; Di Stasio GD; Mansi L
Curr Radiopharm; 2019; 12(2):98-106. PubMed ID: 30727940
[TBL] [Abstract][Full Text] [Related]
12. PET/CT and PET/MRI in neuroendocrine neoplasms.
Rajamohan N; Khasawneh H; Singh A; Suman G; Johnson GB; Majumder S; Halfdanarson TR; Goenka AH
Abdom Radiol (NY); 2022 Dec; 47(12):4058-4072. PubMed ID: 35426497
[TBL] [Abstract][Full Text] [Related]
13. Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy.
Vija L; Dierickx L; Courbon F
Ann Endocrinol (Paris); 2019 Jun; 80(3):166-171. PubMed ID: 31053248
[TBL] [Abstract][Full Text] [Related]
14. Comparison of gallium-68 somatostatin receptor and
Liu X; Li N; Jiang T; Xu H; Ran Q; Shu Z; Wu J; Li Y; Zhou S; Zhang B
Hell J Nucl Med; 2020; 23(2):188-200. PubMed ID: 32716410
[TBL] [Abstract][Full Text] [Related]
15. Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.
Taïeb D; Garrigue P; Bardiès M; Abdullah AE; Pacak K
PET Clin; 2015 Oct; 10(4):477-86. PubMed ID: 26384594
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects.
Park S; Parihar AS; Bodei L; Hope TA; Mallak N; Millo C; Prasad K; Wilson D; Zukotynski K; Mittra E
J Nucl Med; 2021 Oct; 62(10):1323-1329. PubMed ID: 34301785
[TBL] [Abstract][Full Text] [Related]
18.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
19. Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors.
Chan H; Moseley C; Zhang L; Bergsland EK; Pampaloni MH; Van Loon K; Hope TA
Pancreas; 2019 Aug; 48(7):948-952. PubMed ID: 31268975
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors.
Wang L; Tang K; Zhang Q; Li H; Wen Z; Zhang H; Zhang H
Biomed Res Int; 2013; 2013():102819. PubMed ID: 24106690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]